Idera Pharmaceuticals presented preclinical evidence BioPharma Consumer Cyclicals Diversified Financial Macro Markets Software & ServicesApril 14, 2014 Idera Pharmaceuticals presented preclinical evidence Sharing Twitter0 Facebook0 Google +0 Linkedinactive){li-icon[type=linkedin-bug][color=inverse] .background{fill Email this article Print this article Tags B-Cell Lymphoma, biopharmaceutical, Cancer Research, Idera Pharmaceuticals, IDRA, MYD88 L265P mutation
